Advertisement
UK markets close in 5 hours 14 minutes

  • FTSE 100

    8,093.65
    +53.27 (+0.66%)
     

  • FTSE 250

    19,725.36
    +5.99 (+0.03%)
     

  • AIM

    755.40
    +0.71 (+0.09%)
     

  • GBP/EUR

    1.1669
    +0.0024 (+0.21%)
     

  • GBP/USD

    1.2518
    +0.0055 (+0.44%)
     

  • Bitcoin GBP

    50,967.95
    -2,031.07 (-3.83%)
     

  • CMC Crypto 200

    1,361.60
    -20.97 (-1.52%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.82
    +0.01 (+0.01%)
     

  • GOLD FUTURES

    2,337.40
    -1.00 (-0.04%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,979.53
    -109.17 (-0.60%)
     

  • CAC 40

    8,044.68
    -47.18 (-0.58%)
     
Stock:

Trending tickers

Microsoft, Google, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

ImmuPharma licenses lupus drug Lupuzor to Avion in the United States

Reuters

LONDON (Reuters) - British pharmaceutical firm ImmuPharma <IMM.L> said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals.

Avion and ImmuPharma will co-develop Lupuzor, including a new Phase III trail, and Avion will commercialise the drug exclusively in the United States, ImmuPharma said.

The British company said it would receive milestone payments of up to $70 million, comprising $5 million upon regulatory approval and up to $65 million based on sales targets.

(Reporting by Paul Sandle; editing by Kate Holton)